Celulas Genetica licenses new organ regeneration treatment from Chinese BBFITCL

Nov 30 2010

Emerging Healthcare Solutions, Inc. (PinkSheets:EHSI) announced today that its affiliate, Celulas Genetica, purchased a license to develop and market a revolutionary new medical treatment known as the Rutherford Procedure.

“We envision Celulas Genetica playing a major role in our future endeavors.”

The Rutherford Procedure is a groundbreaking organ regeneration treatment being developed to utilize proton-beam technology to destroy diseased organ tissue for regeneration using adult stem cells. Celulas Genetica licensed the procedure from the Chinese firm BBFITCL.

Headquartered in the stem-cell Mecca of Panama City, Panama, Celulas Genetica is a Central American leader in adult stem-cell technology acquisition and development. EHSI signed a profit participation agreement with the company earlier this year.

"The Rutherford Procedure is on the cutting edge of modern medicine, offering the possibility of curing deadly diseases such as liver cirrhosis," said EHSI President and CEO Cindy Morrissey. "Demand is very high for this sort of treatment across the globe."

Emerging Healthcare Solutions keeps a close eye on stem cell research worldwide. Morrissey recently traveled to Europe to meet with scientists, consultants and academics about cutting-edge developments in the healthcare research industry there and to cultivate partnerships with overseas healthcare developers and entrepreneurs. This month, she established EHSI business offices in Frankfurt, Germany, and Warsaw, Poland. Those offices will allow the company to maintain long-term relationships with some of the world's foremost stem-cell researchers and entrepreneurs based in Central and Western Europe.

"Many of the world's leading-edge innovations in stem-cell research are happening outside of the United States, where governments and investors are more supportive," Morrissey said. "We envision Celulas Genetica playing a major role in our future endeavors."

EHSI invests in technology developed to compete in the stem-cell research industry alongside Viacell (NASDAQ:VIAC), Allergan, Inc. (NYSE:AGN), Amgen (NASDAQ:AMGN) and Genzyme (NASDAQ:GENZ).